Latest Breaking News On - Cymabay therapeutics inc - Page 1 : comparemela.com

Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch

Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

FOSTER CITY - Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with.

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months - - Reduction in Patient-Reported Pruritus was.

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis – IT Business Net

CymaBay Therapeutics (NASDAQ:CBAY) Receives New Coverage from Analysts at StockNews.com